• NORTH CAROLINA SOCIETY OF GASTROENTEROLOGY
  • 704.376.3688
  • sbuchanan@meckmed.org
NCSGlogo-300NCSGlogo-only-150NCSGlogo-300NCSGlogo-300
  • Home
  • Events and Education
  • Research
  • About NCSG
    • Board of Directors
    • Grants
    • Partners
    • NCSG Bylaws
JOIN NOW
✕
Categories
  • Primary Biliary Cholangitis
Tags
  • Primary Biliary Cholangitis
Study title A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to evaluate efficacy and safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic Acid
Disease or condition Primary biliary cholangitis
Study type Interventional  (Clinical Trial)
Intervention/treatment Elafibrinor or placebo
Phase 3
Study site Duke University
Study location Durham
Principal investigator name and email Andrew Muir, andrew.muir@duke.edu
Study coordinator name and email Christy Walters, christy.walters@duke.edu
Phone contact 919-668-5499
Clinicaltrials.gov link https://clinicaltrials.gov/ct2/show/NCT04526665

ADDRESS


1112 Harding Place
Suite 100
Charlotte NC 28204

Fax: 704.376.3173

LINKS


Home
Education
Events
Research
JOIN NOW

CONTACT


704.376.3688
sbuchanan@meckmed.org

Copyright: North Carolina Society of Gastroenterology (NCSG)
JOIN NOW